Lumicell Announces FDA Acceptance and Priority Review of New Drug Application for Lumisight ™ Optical Imaging Agent for Breast Cancer

NEWTON, Mass., May 22, 2023—Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced the U.S. Food and Drug Administration (FDA) has accepted and granted...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news